"Inoperable" pancreatic cancer may be treatable after all

Share this article:
"Inoperable" pancreatic cancer may be treatable after all
"Inoperable" pancreatic cancer may be treatable after all

Following radiographic restaging, the majority of pancreatic ductal adenocarcinomas in persons who had previously undergone unsuccessful resection attempts were reclassified as resectable or borderline resectable.


Surgical oncologist Jason B. Fleming, MD, and fellow medical, surgical, and radiation oncologists from the University of Texas M.D. Anderson Cancer Center in Houston, Texas, evaluated 88 patients with pancreatic cancer to determine whether accurate radiographic restaging, multimodality treatment, and advanced surgical technique could offer persons previously deemed unresectable the possibility for curative salvage pancreatectomy. In a statement announcing the group's findings, which were published in Journal of the American College of Surgeons (2012;215[1]:41-51), Fleming commented that the key to screening patients for treatment and staging of their cancer lies in the interpretation of preoperative computed tomography (CT) scans by both radiologist and surgeon to give the surgeon a clear idea of tumor location and vessel involvement before beginning the surgery.


All study participants originally received diagnoses of operable, localized cancer at outside institutions, but attempts at tumor removal were aborted when the initial surgery revealed more extensive disease than originally detected. Through radiographic restaging, Fleming's team confirmed that only seven (8%) tumors were actually locally advanced and unresectable. Nearly all the others (92%) were found to be resectable (n=61) or borderline resectable (n=20). 


A total of 66 patients (81%) subsequently underwent successful reoperative pancrea
tectomy using surgery first (9%) or preoperative chemoradiation (91%). Median overall survival was 29.6 months for the successfully resected patients, compared with 10.6 months for those with locally advanced unresectable disease at initial referral and 5.1 months for those patients who developed metastatic disease before resection. 


The major complication rate was 20%, with three patients (4.5%) dying perioperatively. ONA

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in In the News

Navigator Notes: Distress screening and support

Navigator Notes: Distress screening and support

As patients and oncology care teams strive to keep up with complex treatment plans, symptoms of distress in the patient may be missed. Distress screening tools can help nurse navigators ...

Out-of-pocket costs influence adherence to treatment

Out-of-pocket costs influence adherence to treatment

Many patients skip doses or stop taking medication entirely when their share of the costs becomes too high.

Cancer deaths continue to decline

Cancer deaths continue to decline

The American Cancer Society (ACS) has published its latest annual report on cancer incidence and mortality, and the news is good.